Company: STAA
Filing Date: 2025-12-16
Form Type: DFAN14A
Source: 0001213900-25-122330
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-12-16
Form: DFAN14A
Chunk 2
---
, the Participants’ ability to call the Stockholder Meeting. STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE STOCKHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some
or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC’s
website at https://www.sec.gov/.

Information about the Participants and a description
of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants
with the SEC on November 21, 2025 and is available here.

Exhibit 1

<div align='center'>Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon

ISS Says It Would Not Be “Unreasonable for a Shareholder to Remain Opposed” to the Deal

Broadwood Encourages Shareholders to Follow the Recommendations of Proxy Advisory Firms Glass Lewis and Egan-Jones, Both of Whom Recommend Shareholders Vote “ AGAINST” the Proposed Transaction</div>

NEW YORK – (BUSINESS WIRE) – Broadwood
Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on a report published by Institutional
Shareholder Services Inc. (“ISS”), an independent proxy advisory firm, which reiterates that firm’s significant concerns
regarding the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon
Inc. (“Alcon”) (NYSE: ALC).

ISS stated in its latest report on the proposed
sale of STAAR to Alcon:

“The initial sale process was
deeply flawed, the circumstances create uncertainty about whether the go-shop could have cured concerns, and STAA has provided shareholders
with no reason to rely on its efforts. … [In addition,] it is still difficult to fully assess the adequacy of the offer.”

ISS also made the following additional observations:

| ● | “STAA has made